UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 27.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 150,039 shares of the biopharmaceutical company’s stock after purchasing an additional 32,534 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.31% of Theravance Biopharma worth $1,412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in TBPH. Invesco Ltd. boosted its holdings in Theravance Biopharma by 3.5% in the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 1,576 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Theravance Biopharma by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock valued at $2,766,000 after purchasing an additional 2,060 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma in the fourth quarter worth $25,000. SG Americas Securities LLC lifted its stake in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,349 shares during the period. Finally, Martingale Asset Management L P lifted its stake in shares of Theravance Biopharma by 7.7% during the fourth quarter. Martingale Asset Management L P now owns 58,650 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 4,200 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TBPH has been the subject of a number of research analyst reports. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $11.33.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares in the company, valued at $3,330,342. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $11.25 on Monday. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.82. The company has a market capitalization of $562.51 million, a PE ratio of -11.14 and a beta of -0.09. The company has a fifty day moving average of $9.35 and a 200 day moving average of $9.39.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The company had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Research analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.